

1 Title

2 *The Colloido-Osmotic Pressure as a useful biomarker of fatal outcome in pregnant*
3 *COVID-19 patients*

4 Running title

5 *Fatal outcome in Pregnant women with COVID-19*

6 Authors and institutional affiliations

7 B. Zavala-Barrios^{1**}, A. Cébulo-Vázquez^{2**}, M. García-Espinosa³, F. Caldiño-Soto⁴,
8 Ruth L. Madera Sandoval⁹, L.A. Ramírez-García⁵, I.C. Eláceo-Fernández⁸, O. Moreno-
9 Álvarez⁶, G.M.L. Guerrero-Avendaño⁷, J.C. Briones-Garduño^{8*}

10 ¹Subdirección de Apoyo al Diagnóstico y Tratamiento, ²Servicio de Medicina

11 Genómica, ⁷Dirección General, ⁸Servicio de Ginecología y Obstetricia, Hospital

12 General de México “Dr. Eduardo Liceaga”. Ciudad de Mexico, Mexico

13 ³Servicio de complicaciones de la segunda mitad del embarazo, ⁴División Obstetricia.

14 ⁵Dirección Médica, ⁶Dirección General. UMAE Hospital de Gineco-Obstetricia No. 4

15 “Dr. Luis Castelazo Ayala”. Instituto Mexicano del Seguro Social (IMSS). Ciudad de

16 Mexico, Mexico.

17 ⁹Unidad de Investigación Médica en Inmunoquímica, UMAE Hospital de Especialidades,

18 Centro Médico Nacional Siglo XXI. IMSS. Ciudad de México, México.

19 *Corresponding author

20 J.C. Briones-Garduño

21 E-mail: drcarlosbriones@yahoo.com.mx

22 Cel. 52 55 4458 4640

23 **These authors contributed equally

24 Keywords: COVID-19, pregnancy, USG, Doppler, Blood Gas Test.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25 **Abstract**

26 Background: Pregnancy was considering a health condition that could support high
27 severity in COVID-19, among others the cardiologic and respiratory systems express
28 some physiologic change in the pregnant women and could specially affected in COVID-
29 19. Pregnant women characteristically have an increase volume of blood, with a higher
30 cardiac output and lower peripheral vascular resistance, these could be negative affected
31 by hypoalbuminemia frequently observed in COVID-19. Then, an early recognition of
32 hypoalbuminemia in pregnant women with COVID-19 would help us to predict fatal
33 outcome. Objective: We conduct a study to analyzed the demographic, clinical, blood gas
34 test results, laboratory and ultrasonographic doppler data in pregnant women with
35 COVID-19 that demand medical attention for labor. Study design: Ninety-two pregnant
36 women with COVID-19 were included in our study from may 30th 2020 to august 12th
37 2022, and data was analyzed in survival and fatal outcome patients. Normality test were
38 applied to data and parametric or non-parametric test were used to determine statistical
39 difference between or among data. Results: Demographic and clinical data were quite
40 similar between survival and fatal outcome pregnant patients with COVID-19. Also,
41 blood gas test shown similar results among groups (asymptomatic, mild, or severe
42 patients who survive COVID-19 or fatal outcome patients). We observed that serum
43 albumin was consistently low in pregnant patients with fatal outcome by COVID-19, then
44 based on Total Protein concentration in serum we calculated the colloido-osmotic
45 pressure and we evaluate its utility as predictor of fatal outcome. ROC analysis and
46 Kaplan-Meier of survival curves suggest that the colloido-osmotic pressure could be a
47 potential predictor. Also, we observed an association of low colloido-osmotic pressure
48 and low amniotic fluid index. Conclusion: Our study suggests that early evaluation of

49 pregnant with COVID-19 must include the calculation of colloido-osmotic pressure and
50 the doppler analysis to early recognition of fatal outcome in pregnant women with
51 COVID-19.

52

53 Introduction

54 Since 2019 the high number of persons with SARS-CoV-2 result in a pandemic
55 emergency with loss of millions of lives ¹. Fatal outcome by COVID-19 has been
56 associated with certain comorbidities such as obesity or hypertension among others, also
57 pregnant women may experience a high fatality rate probably because a high
58 susceptibility to inflammation ². During pregnancy, the immune response develops an
59 immunological tolerance and a high level of regulation to inflammatory response,
60 however this delicate balance could negative affected in pregnant women with COVID-
61 19 ³. Also, a profound physiologic regulation in other systems can be observed in
62 pregnancy, which includes the circulatory and respiratory systems ^{4,5}. Pregnant women
63 characteristically have an increase volume of blood, with a higher cardiac output and
64 lower peripheral vascular resistance, also, pregnant women tend to develop a respiratory
65 alkalosis with pH between normal limits, and all these characteristics could be negative
66 affected by COVID-19.

67 COVID-19-associated deaths during pregnancy was increasing worldwide, Karimi et al
68 reported 153 deaths out of 11758 pregnant and postpartum women with COVID-19
69 (1.3%). However, the mortality rate is differential between high- or middle-income
70 countries. The high-income countries show a mortality rate about 0.19%, while in middle-
71 income countries was as high as 8.51% ⁶. In Mexico, from April 2022 to August 2021,
72 389 maternal deaths by COVID-19 were recorded in a population of 20329 pregnant and
73 postpartum women (1.9%) ⁷.

74 Demographic data in pregnant women with COVID-19 shows that they are frequently
75 older than 31 years old ⁸, with a Body Mass Index >30, multiple pregnancy and
76 hypertension ⁸⁻¹⁰. In addition, some social condition in mild-income countries could lead

77 to undernutrition especially in pregnant women, and leading to poor immune response
78 against COVID-19 ^{11,12}. Undernutrition could be recognized by low serum albumin,
79 which is a good predictor for negative outcomes after surgeries ¹³, or infection disease as
80 COVID-19 ¹⁴.

81 In addition, certain laboratory parameters in pregnant women with COVID-19 are useful
82 to detect high risk of fatal outcome, among these parameters the leucocyte count ¹⁵,
83 platelet count ¹⁶ or neutrophil-lymphocyte ratio (NLR)¹⁷ had been reported. Likewise, the
84 evaluation of arterial blood gas parameters is essential to evaluate pregnant women with
85 COVID-19, however, a low number of studies shows the arterial blood gas test in
86 pregnant women with COVID-19. Also, it has been reported that some chemistry
87 parameters can be useful for early detection of severe COVID-19, among them the serum
88 values of creatinine ¹⁸, procalcitonin (PCT) ¹⁹ or albumin ²⁰ had been reported, however,
89 poor analysis is available for pregnant women with COVID-19. Specially the
90 hypoalbuminemia could result in negative changes in pregnant women because it led to
91 a low Colloido-Osmotic Pressure (cCOP). This is a pressure exerted by the protein on the
92 capillary membranes, and could be calculated using the formula 1 of Landis-
93 Pappenheimer, and fatal outcome in trauma patients is frequently observed in patients
94 with values as low as <15 mmHg of cCOP ²¹. A low cCOP could limit the maternal-fetal
95 interchange, compromise the placental perfusion and altering the microvasculature in
96 chorionic villi ²², however, all these changes could closely monitored by doppler
97 ultrasonography, following the blood flow in the: Umbilical artery (UA), uterine artery
98 (UAT), Fetal Middle Cerebral Artery (FMCA), or Amniotic Fluid Index (AFI). Until
99 now, there are few studies that include the ultrasonographic evaluation in pregnant

100 women with COVID-19, and the few reported no differences between SARS-CoV-2-
101 positive pregnant women and controls ²³.
102 Our study analyzed demographic, clinical, laboratory, arterial blood gas test and doppler
103 data in pregnant women with COVID-19 who survive or got a fatal outcome, the results
104 suggest that cCOP can early detect pregnant women with COVID-19 with high
105 probability of having a fatal outcome.

106 **Material and methods**

107 *Patients*

108 This study was conducted by the "Servicio de Ginecología y Obstetricia" at the Hospital
109 General de Mexico "Dr. Eduardo Liceaga" (HGM, Research project: *DI/20112/04/45*),
110 and the Servicio de complicaciones de la segunda mitad del embarazo, División
111 Obstetricia, UMAE Hospital de Gineco-Obstetricia No. 4 "Dr. Luis Castelazo Ayala"
112 (UMAE HGO-4 IMSS. Research project: *R-2020-785-095*). After obtaining a signed
113 informed consent letter, ninety-two women were enrolled and assigned to one of three
114 groups: a) asymptomatic, n=20, b) mild COVID-19, n=56, c) severe COVID-19, n=16,
115 then 6 patients in the severe COVID-19 group got a fatal outcome and was analyzed as a
116 different group. The COVID-19 diagnosis was based on clinical characteristics and
117 positive RT-PCR test for SARS-CoV-2 or radiographic images compatible with COVID-
118 19 disease. Demographic, Clinical and Comorbidities features were recorded.

119 *Blood sample collection*

120 Our study is in accordance with the World Medical Association's Declaration of Helsinki.
121 After the patients signed the informed consent letter, blood specimens were collected in
122 silicone-coated tubes (EDTA or heparinized tubes, BD Vacutainer, N. J, USA), samples

123 were processed immediately after collection.

124 *Arterial Blood Gas test*

125 Heparin blood samples were obtained and blood gas analysis was performed on an
126 ABL90 Flex Plus blood gas analyzer (Radiometer Medical ApS, Bronshoj, Denmark)
127 within 30 min of collect.

128 *Doppler test*

129 Doppler analysis was as D'Antonio reported ²⁴, we performed the analysis using a
130 Samsung HS40 (Samsung Healthcare, N.J, USA) or a Chison EBit 50 (Chison, Jiangsu,
131 China) ultrasound machines. Data was recorded during fetal quiescence, without fetal
132 tachycardia, with the insonation angle kept as close to 0° as possible. FMCA was
133 examined at the point at which it passes the sphenoid wing, close to the circle of Willis,
134 and the UA was examined at a free loop of the umbilical cord. To record the UAT
135 Doppler, the transducer was placed over the iliac fossa and the course of the uterine
136 arteries was followed from the lateral pelvic wall across external iliac artery using color
137 Doppler. Pulsed Doppler was then applied 1 cm medial to the crossover point. When three
138 similar consecutive waveforms were obtained, the PI was measured, and the mean value
139 of the left and right uterine artery PI calculated.

140 *Statistical analysis*

141 Statistical analysis was performed using GraphPad Prism® version 7 software (GraphPad
142 Software, San Diego, CA, USA) and the R i386 3.5.2 terminal (Microsoft corp., Boston,
143 MA, USA.). Categorical variables were expressed as percentages (%), and compared by
144 Fisher's exact test. Non-parametric ANOVA (Kruskal–Wallis test) with Dunn's posttest

145 was applied. Spearman correlation for interest variables was implemented. A $p < 0.05$ was
146 considered statistically significant.

147 **Results**

148 Ninety-two pregnant patients with COVID-19 was attended in the HGM and reviewed
149 with coauthors in the UMAE HGO-4 IMSS, from may 30th 2020 to august 12th 2022. All
150 patients got an RT-PCR+ for SARS-CoV-2 or radiographic imagen diagnostic for SARS-
151 CoV-2 infection. Twenty of the ninety-two pregnant patients in labor without any clinical
152 sign of COVID-19 got a positive result for SARS-CoV-2 PCR test, these asymptomatic
153 patients were included in our study. Table 1 show clinical and laboratory characteristics,
154 no statistical difference was observed for age, body mass index, gestational age, trimester
155 of gestation, weight newborn, or Apgar score among the groups, however, prolonged
156 stays in hospital were observed in severe or fatal outcome patients with COVID-19 than
157 in asymptomatic patients positive for SARS-CoV-2. Also, we observed a similar number
158 of leucocytes and platelets among groups (Table 1). However, the percentage of PMN
159 was higher in patients with severe COVID-19 than in asymptomatic pregnant women.
160 Table 2 shows the results of arterial blood gas test. No statistical significance was
161 observed in pH, PaO₂, saturation of O₂ or lactate among groups, however, severe patients
162 show a higher CO₂ value than mild patients ($p = 0.005$), also, the BE was lower in the mild
163 group than in fatal outcome patients ($p = 0.02$). Results in Table 2 shows that pregnant
164 women developing a respiratory alkalosis probably due by hyperventilation, this
165 respiratory condition is quite frequent in pregnant patients and pH values are in normal
166 limits.

167 Regarding chemistry parameters, we observed that creatinine and D-Dimer concentration
168 were similar among groups (Table 3), however, procalcitonin was higher in severe
169 COVID-19 than in asymptomatic patients ($p=0.040$). Also, the asymptomatic patients
170 show the highest serum albumin concentration, while the lowest serum albumin was in
171 fatal outcome pregnant women with COVID-19 (Table 3).

172 Fig. 1A shows the cCOP in mild-severe COVID-19 pregnant women is higher than in
173 fatal outcome pregnant women with COVID-19. Moreover, moderate correlation ($r=$
174 0.45) among cCOP and amniotic fluid index, was observed (fig. 1B) in patients with mild,
175 severe and fatal outcome.

176 Also, the ROC curve analysis show that the AUC was 53.2%, and the optimal cutoff was
177 calculated in accordance with Youden index 15.7, with a confidence interval of 77.8%,
178 57.1%. Also, a survival curve of cCOP was analyzed. Kaplan-Meier of survival curves
179 were made according to the optimal cutoff, and hazard ratio expressed in percentage,
180 $p<0.05$. The median days of survival was 340 for the lower risk group and a 31% of risk
181 for the patients with value greater than 15.7.

182 Fig. 2 shows the ultrasonographic analysis in survivor pregnant women with COVID-19
183 or asymptomatic patients SARS-CoV-2 positive. Similar results were observed for UA,
184 UAT, and FMCA among groups, however, the amniotic fluid index show statistical
185 difference, were asymptomatic patients show a higher index than in severe COVID-19
186 patients ($p=0.01$) or higher index in mild COVID-19 patients than in severe COVID-19
187 patients ($p=0.02$).

188 **Discussion**

189 *Principal Findings*

190 The early recognition of severe or critical COVID-19 in pregnant women would help us
191 to get a lower maternal mortality by COVID-19, or predict fatal outcome in pregnant
192 women with COVID-19. Our study shows that long stay in hospital (media=14-15 days)
193 is characteristic of patients with severe COVID-19 or fatal outcome (Table 1). We also
194 observed that arterial blood gas test was quite similar among pregnant women with
195 COVID-19 even in those who got a fatal outcome (Table 2). In agreement with the
196 literature hypoalbuminemia was noted specially in patients with severe COVID-19 or
197 those who got fatal outcome (Table 3). We calculated the Colloido-osmotic pressure in
198 mild and severe COVID-19 and compared with patients with fatal outcome, a significant
199 difference was observed between those groups, and association between cCOP and
200 amniotic fluid index was observed (Figure 1). Unfortunately, a doppler test was not
201 applied on patients with fatal outcome by COVID-19, however, we observed that the
202 amniotic fluid index was lower according to severity of COVID-19 (Figure 2).

203 **Results**

204 Several studies show the mean of age of pregnant women with COVID-19 is around 30
205 years old ^{8,15,25-31}, and most pregnant women with COVID-19 were aged between 20 to
206 39 years ⁹, our study also show that pregnant women with COVID-19 or asymptomatic
207 patients were around 30 years old (Table 1). Comorbidities as obesity has been associated
208 to suffer severe COVID-19 in pregnant women ⁸, and been in a higher risk for maternal
209 death ³², and some studies show that BMI over 30 is frequently observed in pregnant
210 women COVID-19 patients ^{28,31}, our study also observed this condition (Table 1). The
211 most of literature show that pregnant women with COVID-19 have a mean of gestational
212 age around 30 weeks ^{28,29}, or higher gestational age than 30 weeks ^{26,27}, as we expect the
213 most of maternal death in pregnant women with COVID-19 has been observed in the
214 third trimester of pregnancy, however, other studies did not show a high number of fatal

215 outcomes by COVID-19 in the third trimester³³⁻³⁶. Maternal mortality could be as low as
216 0.2 to 2%^{10,37-39}, or as high as 10 to 20%^{6,40-42} according with low- or middle-income⁴²⁻
217 ⁴⁴. Our study shows similar data for gestational age, fatal outcome by trimester and
218 maternal mortality as a middle-income country, these observation in a sense validate our
219 study and could help to increase the number of observations for pregnant women with
220 COVID-19 in the very first wave when collection of data was so difficult.

221 Early evaluation of blood gas test in pregnant women with COVID-19 seems to be critical
222 and could help to recognize severity. Both alkalosis and acidosis were observed in
223 patients with COVID-19 in general population, and alkalosis was observed in 54.3% of
224 the subjects⁴⁵. Also, ketoacidosis has been reported in pregnant women with COVID-19
225 which is associated with diabetes, hyperglycemia and ketosis^{46,47}. However, our result
226 did not show great differences among groups, indicating that blood gas parameters was
227 not altered even with variants of SARS-CoV-2 that express high maternal mortality. More
228 observations must do it to clarify this observation.

229 Blood cell count had been analyzed in patients with COVID-19, some authors show that
230 white blood cell count is higher in pregnant than in non-pregnant women with COVID-
231 19²⁷, however, other studies show that leucocytosis was not observed in pregnant women
232 with COVID-19^{27,35}, in contrast, some pregnant women with COVID-19 show
233 lymphopenia⁴⁸. In agreement with Wang Z et. al. and Yan J et. al. we did not observe
234 great differences in leucocytes counts among the groups. Finally, has been reported that
235 a lower platelet count is observed in patients with severe COVID-19^{16,18}, while other
236 study show that the platelet count was similar in pregnant women with and without
237 SARS-CoV-2 infection⁴⁹. In agreement with Covali R et. al. we did not observed
238 difference in the platelet count of pregnant women with COVID-19, no difference was

239 observed among groups by severity or fatal outcome, this is probably because the
240 relatively small number of patients. More studies are necessary to clarify if low platelet
241 count is a good predictor of fatal outcome in pregnant women.

242 Shmakov RG et. al. shows a similar D-Dimer concentration among asymptomatic, mild,
243 moderate and severe COVID-19 in pregnant women ²⁸, and our study agrees with this
244 observation. Another potential biomarker is the PCT, however, the value of this
245 biomarker to predict severity in COVID-19 show some contradictory results in general
246 population ¹⁹, and in pregnant women with COVI-19, PCT levels was similar between
247 pregnant and non-pregnant women with COVID-19 ^{41,50}, while some other study show a
248 difference between them ²⁷. Because the PCT was similar among mild, moderate and
249 severe COVID-19 in pregnant women ²⁸, the result suggest that PCT is not able to
250 discriminate the mild from severe COVID-19 in pregnant women, our study agrees with
251 this observation, we observed that the highest PCT concentration was in the mild cases,
252 in the mild group we observed patients with PCT values quite similar to severe COVID-
253 19 patients (range 0.010-11.0 ng/mL) and a subgroup of mild COVID-19 patients with
254 high values of PCT (918.0-5227.0 ng/mL), suggesting that this second subgroup got a
255 bacterial infection, however, we could not get a positive bacterial culture on them,
256 interestingly, none of this potential over infected patients got a fatal outcome, suggesting
257 that even in the case of double infection the immune system of pregnant women will be
258 sufficient to solve the infection challenge.

259 Hypoalbuminemia has been associated to disease severity in COVID-19 ^{20,28,51}, the
260 expression of hypoalbuminemia on admission is more frequent in non-survivors than
261 survivors, and could be useful as an early predictor of mortality in COVID-19 ⁵²⁻⁵⁴. In
262 contrast, a high level of albumin on admission is associated with a lower risk of Acute

263 Respiratory Distress Syndrome and admission to ICU ⁵³. Lower albumin concentration
264 was reported in pregnant than in non-pregnant women with COVID-19 without fatal
265 outcome ²⁷, our results show that a hypoalbuminemia as low as 2.5 could result in low
266 colloido-osmotic pressure and finally a fatal outcome. The colloido-osmotic pressure is
267 easily evaluated among patients, and our study propose its routine analysis to predict fatal
268 outcome in pregnant women with COVID-19. Moreover, low cCOP in COVID-19 could
269 lead to impaired placental perfusion. It has been reported that SARS-CoV-2 infection
270 does not affect the blood flow in the umbilical vein ⁵⁵, also, in pregnant women recovered
271 from COVID-19 the pulsatility and resistance indices of umbilical and uterine artery show
272 a significant increase than in controls ⁵⁶. In contrast, Soto-Torres et. al. report that Doppler
273 evaluation was similar between pregnant women with SARS-CoV-2 infection and
274 controls ²³. In agreement with Soto-Torres et. al. we observed that the umbilical artery,
275 uterine artery, and fetal middle cerebral artery the blood flow were similar in pregnant
276 and non-pregnant COVID-19 women, however, we observed that the Amniotic Fluid
277 Index was lower in severe than in mild or asymptomatic COVID-19 patients, this lower
278 amniotic fluid index in severe COVID-19 patients could expressed or been the Fetal
279 Inflammatory Response Syndrome by viral infection.

280

281 ***Clinical implications***

282 Two conditions could explain the high maternal mortality in our hospital a) because we
283 are in a middle-income country and b) because our hospital is a national reference center.
284 We were able to classify our patients in asymptomatic, mild, and severe COVID-19
285 patients; however, some clinical characteristics of our patients were quite similar among
286 groups as age, BMI, gestational age, weight newborn, Apgar score etc. indicating that
287 those characteristics have low value to early recognize patients with high potential for a

288 fatal outcome. Also, our study show that pregnant women tend to respiratory alkalosis
289 that is not necessarily deteriorated by COVID-19. Despite a limited respiratory condition
290 in pregnant women, it seems that gas test in pregnant women with COVID-19 is similar
291 than in women in general population with COVID-19. Some other laboratory analysis as
292 the blood count was also analyzed, we did not observe leukocytosis or lymphopenia in
293 pregnant women with COVID-19, and no association with severity was observed,
294 probably because a small number of patients in our study. We observed the highest
295 neutrophilia in pregnant women with severe COVID-19, however, neutropenia and not
296 neutrophilia was observed in pregnant women with COVID-19 and fatal outcome.
297 Neutrophils are important innate cells that participate in many mechanisms related with
298 inflammation, its high or low number in pregnant women with COVID-19 seems to be
299 important for limit the infection, however, we need more analysis in pregnant women to
300 clarify if neutropenia and neutrophilia are supporter of pathophysiology in COVID-19.
301 Our results suggest that Basic Doppler evaluation could be useful to early recognition of
302 severe COVID-19 in pregnant women.

303

304 ***Research implications***

305 We do not know when the next pandemic comes, but patients with comorbidities or
306 special conditions as pregnancy will be affected. Due the complex condition in prenatal
307 surveillance, labor and postpartum period during pandemic for COVID-19 many
308 opportunities of do deeper analysis of data o searching for a no-conventional assessment
309 were lost, and data in pregnant women with COVID-19 is scarce. Medical attention of
310 pregnant patients must include a holistic view, with strict attention to ethical and patient's
311 rights, and then collect any data that potentially could help to understand the new disease
312 like COVID-19 and minimize the fatal outcomes.

313

314 ***Strengths and limitations***

315 Our study has some limitations and strengths, the number of observations is relatively
316 low (n=92) with six fatal outcomes included (6.5%), because early in the pandemic a
317 medical treatment was not established and medical support was apply after some days of
318 the initial COVID-19 symptoms a high percentage of fatal outcome was observed,
319 however, our study also show demographic, clinical and laboratory data observed at the
320 very early time (in the second wave) of pandemic of COVID-19 in Mexico, and when
321 vaccination was not available, these conditions could help us to understand the natural
322 progression in pregnant women with COVID-19.

323

324 ***Conclusions***

325 A high number of comorbidities is observed in COVID-19 patients with high severity,
326 and also the pregnancy could allow a severe presentation of COVID-19. However, the
327 frequency of severe cases in pregnant women with COVID-19 is similar than in general
328 population^{15,41,57}, due to the pandemic condition many studies in pregnant women with
329 COVID-19 show missing or not collected data, our data show that hypoalbuminemia and
330 the cCOP could help to early recognize patients with high risk of fatal outcome, more
331 studies are necessary to know if pregnancy must not take as a comorbidity that increase
332 the risk of severe COVID-19.

333

334 **Contributors**

335 BZB, ACV and JCBG conceived and designed the study and contributed to data analysis.
336 BZB and ACV wrote the first version of manuscript. MGE, FCS, LARG, RLMS, JCBG,
337 OMA, and GMLGA contributed to a critical revision of the report. MGE, FCS, LARG,
338 ICEF, JCBG, BZB, and OMA contributed to the clinical evaluation of patients and
339 supervision of medical treatments and patient care. RLMS contributed to do the statistical
340 analysis and graph data. All authors reviewed the final version. JCBG reviewed and
341 approved the final version.

342

343 **Acknowledgments**

344 The authors extend gratitude to the staff at Gynecology & Obstetrics Department in the
345 General Hospital of Mexico “Dr. Eduardo Liceaga” and Gynecology & Obstetric
346 Hospital No. 4 UMAE “Dr. Luis Castelazo Ayala”.

347

348 Declaration of interests

349 All authors declare no competing interests.

350

351

References

352

- 353 1. WHO. WHO Coronavirus (COVID-19) Dashboard. <https://covid19.who.int/>
- 354 2. Adab P, Haroon S, O'Hara ME, Jordan RE. Comorbidities and covid-19. *BMJ*.
355 Jun 15 2022;377:o1431. doi:10.1136/bmj.o1431
- 356 3. Cerbulo-Vazquez A, Garcia-Espinosa M, Briones-Garduno JC, et al. The
357 percentage of CD39+ monocytes is higher in pregnant COVID-19+ patients than in
358 nonpregnant COVID-19+ patients. *PLoS One*. 2022;17(7):e0264566.
359 doi:10.1371/journal.pone.0264566
- 360 4. Hegewald MJ, Crapo RO. Respiratory physiology in pregnancy. *Clin Chest Med*.
361 Mar 2011;32(1):1-13. doi:10.1016/j.ccm.2010.11.001
- 362 5. LoMauro A, Aliverti A. Respiratory physiology in pregnancy and assessment of
363 pulmonary function. *Best Pract Res Clin Obstet Gynaecol*. Jun 27
364 2022;doi:10.1016/j.bpobgyn.2022.05.007
- 365 6. Karimi L, Makvandi S, Vahedian-Azimi A, Sathyapalan T, Sahebkar A. Effect of
366 COVID-19 on Mortality of Pregnant and Postpartum Women: A Systematic Review and
367 Meta-Analysis. *J Pregnancy*. 2021;2021:8870129. doi:10.1155/2021/8870129
- 368 7. Epidemiología CNEdGySRDGD. Aviso Epidemiológico COVID-19.
369 [https://www.gob.mx](https://www.gob.mx/uploads/attachment_data/file) › uploads › attachment › file
- 370 8. Epelboin S, Labrosse J, De Mouzon J, et al. Obstetrical outcomes and maternal
371 morbidities associated with COVID-19 in pregnant women in France: A national
372 retrospective cohort study. *PLoS Med*. Nov 2021;18(11):e1003857.
373 doi:10.1371/journal.pmed.1003857
- 374 9. Galang RR, Newton SM, Woodworth KR, et al. Risk Factors for Illness Severity
375 Among Pregnant Women With Confirmed Severe Acute Respiratory Syndrome
376 Coronavirus 2 Infection-Surveillance for Emerging Threats to Mothers and Babies
377 Network, 22 State, Local, and Territorial Health Departments, 29 March 2020-5 March
378 2021. *Clin Infect Dis*. Jul 15 2021;73(Suppl 1):S17-S23. doi:10.1093/cid/ciab432
- 379 10. Overton EE, Goffman D, Friedman AM. The Epidemiology of COVID-19 in
380 Pregnancy. *Clin Obstet Gynecol*. Mar 1 2022;65(1):110-122.
381 doi:10.1097/GRF.0000000000000674
- 382 11. James PT, Ali Z, Armitage AE, et al. The Role of Nutrition in COVID-19
383 Susceptibility and Severity of Disease: A Systematic Review. *J Nutr*. Jul 1
384 2021;151(7):1854-1878. doi:10.1093/jn/nxab059
- 385 12. Don BR, Kaysen G. Serum albumin: relationship to inflammation and nutrition.
386 *Semin Dial*. Nov-Dec 2004;17(6):432-7. doi:10.1111/j.0894-0959.2004.17603.x
- 387 13. Gibbs J, Cull W, Henderson W, Daley J, Hur K, Khuri SF. Preoperative serum
388 albumin level as a predictor of operative mortality and morbidity: results from the
389 National VA Surgical Risk Study. *Arch Surg*. Jan 1999;134(1):36-42.
390 doi:10.1001/archsurg.134.1.36

- 391 14. Mentella MC, Scaldaferrri F, Gasbarrini A, Miggiano GAD. The Role of Nutrition
392 in the COVID-19 Pandemic. *Nutrients*. Mar 27 2021;13(4)doi:10.3390/nu13041093
- 393 15. Amini Moghadam S, Dini P, Nassiri S, Motavaselian M, Hajibaba M, Sohrabi M.
394 Clinical features of pregnant women in Iran who died due to COVID-19. *Int J Gynaecol*
395 *Obstet*. Feb 2021;152(2):215-219. doi:10.1002/ijgo.13461
- 396 16. Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe
397 coronavirus disease 2019 (COVID-19) infections: A meta-analysis. *Clin Chim Acta*. Jul
398 2020;506:145-148. doi:10.1016/j.cca.2020.03.022
- 399 17. Lasser DM, Chervenak J, Moore RM, et al. Severity of COVID-19 Respiratory
400 Complications during Pregnancy are Associated with Degree of Lymphopenia and
401 Neutrophil to Lymphocyte Ratio on Presentation: A Multicenter Cohort Study. *Am J*
402 *Perinatol*. Oct 2021;38(12):1236-1243. doi:10.1055/s-0041-1732421
- 403 18. Tufa A, Gebremariam TH, Manyazewal T, et al. Limited value of neutrophil-to-
404 lymphocyte ratio and serum creatinine as point-of-care biomarkers of disease severity
405 and infection mortality in patients hospitalized with COVID-19. *PLoS One*.
406 2022;17(10):e0275391. doi:10.1371/journal.pone.0275391
- 407 19. Wolfisberg S, Gregoriano C, Schuetz P. Procalcitonin for individualizing
408 antibiotic treatment: an update with a focus on COVID-19. *Crit Rev Clin Lab Sci*. Jan
409 2022;59(1):54-65. doi:10.1080/10408363.2021.1975637
- 410 20. Johnson AS, Winlow W. COVID-19 vulnerabilities are intensified by declining
411 human serum albumin levels. *Exp Physiol*. Jul 2022;107(7):674-682.
412 doi:10.1113/EP089703
- 413 21. Alberto Basilio Olivares JCB, Jesús Antonio Jiménez Origel,, Ponce MADdL. La
414 presión coloidosmótica (PCO) como indicador
415 pronóstico en trauma. Reporte preliminar. *Rev Asoc Mex Med Crit y Ter Int*.
416 2012;26(4):230-233.
- 417 22. Acharya G, Sonesson SE, Flo K, Rasanen J, Odibo A. Hemodynamic aspects of
418 normal human fetoplacental (umbilical) circulation. *Acta Obstet Gynecol Scand*. Jun
419 2016;95(6):672-82. doi:10.1111/aogs.12919
- 420 23. Soto-Torres E, Hernandez-Andrade E, Huntley E, Mendez-Figueroa H, Blackwell
421 SC. Ultrasound and Doppler findings in pregnant women with SARS-CoV-2 infection.
422 *Ultrasound Obstet Gynecol*. Jul 2021;58(1):111-120. doi:10.1002/uog.23642
- 423 24. D'Antonio F, Rizzo G, Gustapane S, et al. Diagnostic accuracy of Doppler
424 ultrasound in predicting perinatal outcome in pregnancies at term: A prospective
425 longitudinal study. *Acta Obstet Gynecol Scand*. Jan 2020;99(1):42-47.
426 doi:10.1111/aogs.13705
- 427 25. Dawood FS, Varner M, Tita A, et al. Incidence and Clinical Characteristics of and
428 Risk Factors for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
429 Infection Among Pregnant Individuals in the United States. *Clin Infect Dis*. Jul 6
430 2022;74(12):2218-2226. doi:10.1093/cid/ciab713
- 431 26. Zhang J, Zhang Y, Ma Y, et al. The associated factors of cesarean section during
432 COVID-19 pandemic: a cross-sectional study in nine cities of China. *Environ Health Prev*
433 *Med*. Oct 10 2020;25(1):60. doi:10.1186/s12199-020-00899-w
- 434 27. Wang Z, Wang Z, Xiong G. Clinical characteristics and laboratory results of
435 pregnant women with COVID-19 in Wuhan, China. *Int J Gynaecol Obstet*. Sep
436 2020;150(3):312-317. doi:10.1002/ijgo.13265

- 437 28. Shmakov RG, Prikhodko A, Polushkina E, et al. Clinical course of novel COVID-
438 19 infection in pregnant women. *J Matern Fetal Neonatal Med.* Dec 2022;35(23):4431-
439 4437. doi:10.1080/14767058.2020.1850683
- 440 29. Pierce-Williams RAM, Burd J, Felder L, et al. Clinical course of severe and
441 critical coronavirus disease 2019 in hospitalized pregnancies: a United States cohort
442 study. *Am J Obstet Gynecol MFM.* Aug 2020;2(3):100134.
443 doi:10.1016/j.ajogmf.2020.100134
- 444 30. Capobianco G, Saderi L, Aliberti S, et al. COVID-19 in pregnant women: A
445 systematic review and meta-analysis. *Eur J Obstet Gynecol Reprod Biol.* Sep
446 2020;252:543-558. doi:10.1016/j.ejogrb.2020.07.006
- 447 31. Afshar Y, Gaw SL, Flaherman VJ, et al. Clinical Presentation of Coronavirus
448 Disease 2019 (COVID-19) in Pregnant and Recently Pregnant People. *Obstet Gynecol.*
449 Dec 2020;136(6):1117-1125. doi:10.1097/AOG.0000000000004178
- 450 32. Mendez-Dominguez N, Santos-Zaldivar K, Gomez-Carro S, Datta-Banik S,
451 Carrillo G. Maternal mortality during the COVID-19 pandemic in Mexico: a preliminary
452 analysis during the first year. *BMC Public Health.* Jul 2 2021;21(1):1297.
453 doi:10.1186/s12889-021-11325-3
- 454 33. Gupta V, Yadav Y, Sharma R, Mishra M, Ambedkar D, Gupta V. Maternal and
455 Perinatal Outcomes of Hospitalized COVID-19 Positive Pregnant Women. *Cureus.* Feb
456 2022;14(2):e21817. doi:10.7759/cureus.21817
- 457 34. DeBolt CA, Bianco A, Limaye MA, et al. Pregnant women with severe or critical
458 coronavirus disease 2019 have increased composite morbidity compared with
459 nonpregnant matched controls. *Am J Obstet Gynecol.* May 2021;224(5):510 e1-510 e12.
460 doi:10.1016/j.ajog.2020.11.022
- 461 35. Yan J, Guo J, Fan C, et al. Coronavirus disease 2019 in pregnant women: a report
462 based on 116 cases. *Am J Obstet Gynecol.* Jul 2020;223(1):111 e1-111 e14.
463 doi:10.1016/j.ajog.2020.04.014
- 464 36. London V, McLaren R, Jr., Atallah F, et al. The Relationship between Status at
465 Presentation and Outcomes among Pregnant Women with COVID-19. *Am J Perinatol.*
466 Aug 2020;37(10):991-994. doi:10.1055/s-0040-1712164
- 467 37. Metz TD, Clifton RG, Hughes BL, et al. Association of SARS-CoV-2 Infection
468 With Serious Maternal Morbidity and Mortality From Obstetric Complications. *JAMA.*
469 Feb 22 2022;327(8):748-759. doi:10.1001/jama.2022.1190
- 470 38. Borges Charepe N, Queiros A, Alves MJ, et al. One Year of COVID-19 in
471 Pregnancy: A National Wide Collaborative Study. *Acta Med Port.* May 2
472 2022;35(5):357-366. doi:10.20344/amp.16574
- 473 39. Juan J, Gil MM, Rong Z, Zhang Y, Yang H, Poon LC. Effect of coronavirus
474 disease 2019 (COVID-19) on maternal, perinatal and neonatal outcome: systematic
475 review. *Ultrasound Obstet Gynecol.* Jul 2020;56(1):15-27. doi:10.1002/uog.22088
- 476 40. Leung C, Simoes ESAC, Oliveira EA. Are in-hospital COVID-19-related
477 mortality and morbidity in pregnancy associated with gestational age? *Ultrasound Obstet*
478 *Gynecol.* Aug 2022;60(2):234-242. doi:10.1002/uog.24931
- 479 41. Khoiwal K, Ravi AK, Arora S, et al. Impact of Pregnancy on Susceptibility and
480 Severity of COVID-19: A Hospital-Based Prospective Observational Study. *Cureus.* Apr
481 2022;14(4):e24281. doi:10.7759/cureus.24281
- 482 42. Nakamura-Pereira M, Betina Andreucci C, de Oliveira Menezes M, Knobel R,
483 Takemoto MLS. Worldwide maternal deaths due to COVID-19: A brief review. *Int J*
484 *Gynaecol Obstet.* Oct 2020;151(1):148-150. doi:10.1002/ijgo.13328

- 485 43. Takemoto MLS, Menezes MO, Andreucci CB, et al. Maternal mortality and
486 COVID-19. *J Matern Fetal Neonatal Med.* Jun 2022;35(12):2355-2361.
487 doi:10.1080/14767058.2020.1786056
- 488 44. Maza-Arnedo F, Paternina-Caicedo A, Sosa CG, et al. Maternal mortality linked
489 to COVID-19 in Latin America: Results from a multi-country collaborative database of
490 447 deaths. *Lancet Reg Health Am.* Aug 2022;12:100269.
491 doi:10.1016/j.lana.2022.100269
- 492 45. Sanghani H, Bansal S, Parmar V, Shah R. Study of Arterial Blood Gas Analysis
493 in Moderate-to-Severe COVID-19 Patients. *Cureus.* Jul 2022;14(7):e26715.
494 doi:10.7759/cureus.26715
- 495 46. van Amesfoort JE, Werter DE, Painter RC, Hermans FJR. Severe metabolic
496 ketoacidosis as a primary manifestation of SARS-CoV-2 infection in non-diabetic
497 pregnancy. *BMJ Case Rep.* Apr 19 2021;14(4)doi:10.1136/bcr-2021-241745
- 498 47. Pikovskiy M, Tan MY, Ahmed A, Sykes L, Agha-Jaffar R, Yu CKH. Euglycaemic
499 ketoacidosis in pregnant women with COVID-19: two case reports. *BMC Pregnancy
500 Childbirth.* Jun 16 2021;21(1):427. doi:10.1186/s12884-021-03928-w
- 501 48. Al-Saadi E, Abdunabi MA. Hematological changes associated with COVID-19
502 infection. *J Clin Lab Anal.* Jan 2022;36(1):e24064. doi:10.1002/jcla.24064
- 503 49. Covali R, Socolov D, Socolov R, et al. Complete Blood Count Peculiarities in
504 Pregnant SARS-CoV-2-Infected Patients at Term: A Cohort Study. *Diagnostics (Basel).*
505 Dec 30 2021;12(1)doi:10.3390/diagnostics12010080
- 506 50. Asghar MS, Siddiqui MA, Iqbal S, et al. COVID-19 infection among pregnant
507 and non-pregnant women: Comparison of biochemical markers and outcomes during
508 COVID-19 pandemic, A retrospective cohort study. *Ann Med Surg (Lond).* Apr
509 2022;76:103527. doi:10.1016/j.amsu.2022.103527
- 510 51. Xu Y, Yang H, Wang J, et al. Serum Albumin Levels are a Predictor of COVID-
511 19 Patient Prognosis: Evidence from a Single Cohort in Chongqing, China. *Int J Gen
512 Med.* 2021;14:2785-2797. doi:10.2147/IJGM.S312521
- 513 52. Viana-Llamas MC, Arroyo-Espliguero R, Silva-Obregon JA, et al.
514 Hypoalbuminemia on admission in COVID-19 infection: An early predictor of mortality
515 and adverse events. A retrospective observational study. *Med Clin (Barc).* May 7
516 2021;156(9):428-436. doi:10.1016/j.medcli.2020.12.018
- 517 53. Kheir M, Saleem F, Wang C, Mann A, Chua J. Higher albumin levels on
518 admission predict better prognosis in patients with confirmed COVID-19. *PLoS One.*
519 2021;16(3):e0248358. doi:10.1371/journal.pone.0248358
- 520 54. Huang J, Cheng A, Kumar R, et al. Hypoalbuminemia predicts the outcome of
521 COVID-19 independent of age and co-morbidity. *J Med Virol.* Oct 2020;92(10):2152-
522 2158. doi:10.1002/jmv.26003
- 523 55. Rizzo G, Mappa I, Pietrolucci ME, Lu JLA, Makatsarya A, D'Antonio F. Effect
524 of SARS-CoV-2 infection on fetal umbilical vein flow and cardiac function: a prospective
525 study. *J Perinat Med.* May 25 2022;50(4):398-403. doi:10.1515/jpm-2021-0657
- 526 56. Anuk AT, Tanacan A, Yetiskin FDY, et al. Doppler assessment of the fetus in
527 pregnant women recovered from COVID-19. *J Obstet Gynaecol Res.* May
528 2021;47(5):1757-1762. doi:10.1111/jog.14726
- 529 57. Hessami K, Homayoon N, Hashemi A, Vafaei H, Kasraeian M, Asadi N. COVID-
530 19 and maternal, fetal and neonatal mortality: a systematic review. *J Matern Fetal
531 Neonatal Med.* Aug 2022;35(15):2936-2941. doi:10.1080/14767058.2020.1806817
532

534 **Table 1. Clinical and laboratory characteristics of pregnant women with COVID-**
 535 **19**

	Survivor				
	Asymptomatic (n=20) ^a	Mild (n=56) ^b	Severe (n=10) ^c	Fatal Outcome (n=6) ^d	<i>p</i>
Age (years)	29.1±4.7	28.8±6.8	31.8±4.7	30.5±4.0	ns
BMI	30.3±6.2	30.5±5.9	28.3±3.9	25.9±4.3	ns
Gestational age (Weeks)	35.1±7.4	32.5±8.0	30.6±6.7	28.5±6.1	ns
1st trimester	1	2	0	0	
2nd trimester	1	6	2	2	ns
3rd trimester	18	47	7	4	
Weight Newborn (gr)	2869±754	2730±605	2038±550	1817±814	ns
Apgar score	7.5±1.5	7.9±1.0	4.6±4.1	7.5±1.0	ns
Hospital days	2.8±1.6	5.4±5.8	14.3±8.0	15.6±9.7	a vs c <0.0001 a vs d 0.004 b vs c 0.0009
Leucocytes (10³xμL)	9.2±2.1	7.9±2.7	9.9±4.1	10.2±4.4	ns
PLT (10³xμL)	259±90.7	222.8±87.4	217.9±47.5	211.7±73.1	ns

PMN (%)	75.3±8.2	73.7±18.0	85.6±7.6	56.6±41.7	a vs c
					0.048

536 BMI; Body Mass Index. Kruskal–Wallis test and Dunn's multiple comparisons test. Significant $p < 0.05$.
 537 Mean±SD.

538

539

540

Table 2. Arterial Blood Gas parameters of pregnant women with COVID-19

	Survivor				<i>p</i>
	Asymptomatic (n=20) ^a	Mild (n=56) ^b	Severe (n=10) ^c	Fatal Outcome (n=6) ^d	
pH	7.3±0.04	7.3±0.03	7.3±0.08	7.4±0.08	ns
CO₂	32.0±2.3	27.8±4.0	34.3±6.9	31.4±6.4	b vs c 0.005
O₂	66.1±31.1	78.3±16.9	64.2±15.2	65.1±21.3	ns
Sat O₂	79.8±22.6	85.6±22.4	84.0±19.5	83.8±16.6	ns
Lactate	2.1±0.8	10.0±26	0.7±5.4	2.4±1.5	ns
BE	-6.8±3.3	-6.6±3.5	-4.5±3.6	-2.9±1.3	b vs d 0.023

541 BE; Basic excess. Kruskal–Wallis test and Dunn's multiple comparisons test. Significant $p < 0.05$.
 542 Mean±SD.

543

544

Table 3. Clinical chemistry parameters of pregnant women with COVID-19


	Survivor				<i>p</i>
	Asymptomatic (n=20) ^a	Mild (n=56) ^b	Severe (n=10) ^c	Fatal Outcome (n=6) ^d	
Creatinine (mg/dL)	0.5±0.08	0.2±1.7	0.8±0.8	0.5±0.2	ns
D-Dimer (ng/mL)	2261±1254	2022±2035	3303±3825	11360±17192	ns

PCT	0.07±0.06	496.2±1129	1.3±2.7	0.3±0.1	a vs c
(ng/mL)					0.040
Albumin	3.2±0.2	3.1±0.4	2.7±0.3	2.6±0.1	a vs c
(g/dL)					0.021
					a vs d
					0.005
					b vs c
					0.036
					b vs d
					0.010

545 PCT; Procalcitonin. Kruskal–Wallis test and Dunn’s multiple comparisons test. Significant $p < 0.05$.
 546 Mean±SD.

547


548 **Figure legends**



549

550 **Fig. 1. Colloido-Osmotic Pressure calculated in severe and fatal outcome pregnant women with**
 551 **COVID-19.** The cCOP was calculated as described in the methods. A) Pregnant women with Mild-Severe
 552 COVID-19 have a higher cCOP than in pregnant women with fatal outcome, B) Spearman correlation
 553 between cCOP and amniotic fluid index. The correlation value (among mild, severe COVID-19 and fatal
 554 outcome patients) suggesting a medium correlation, $p = 0.22$. The results are expressed as the mean±SD.
 555 Significance value was $p < 0.05$. U Mann-Whitney tests were calculated.

556



557

558 **Fig. 2. Maternal-fetal Doppler test in pregnant women with COVID-19.** Pregnant women were tested
559 by USG as described in the methods. Doppler analysis is shown for A) Umbilical artery, B) Uterine artery,
560 C) Fetal middle cerebral artery, and D) Amniotic fluid index. Dash line indicate normal limits. The results
561 are expressed as the mean±SD. Significance value was $p<0.05$. Kruskal–Wallis and Dunn's multiple
562 comparisons tests were calculated.